Licensing Opportunities

Technologies available for partnering or licensing:

  • Circulating tumour DNA for monitoring disease burden and genomic changes in cancer
  • Novel inhibitors of perforin
  • Innovative foldamers targeting CCK-2 as theranostic agents in cancer
  • IRF9 as a novel prognostic biomarker in breast cancer

Tangible materials available for licensing:

  • Fully human monoclonal antibody against Ryk
  • Novel leukaemia stem cell line

Peter Mac has a broad portfolio of early stage research opportunities available for partnering and/or licensing.

For any licensing and partnering enquiries, please contact the Commercialisation Team.